These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 28986189)

  • 21. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical analysis of the usefulness of letermovir for prevention of cytomegalovirus infection after haploidentical hematopoietic stem cell transplantation].
    Ma R; He Y; Wang HF; Bai L; Han W; Cheng YF; Liu KY; Xu LP; Zhang XH; Wang Y; Zhang YY; Wang FR; Mo XD; Yan CH; Huang XJ; Sun YQ
    Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):826-832. PubMed ID: 37394853
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
    Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
    Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
    Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
    Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.
    Cowley NJ; Owen A; Shiels SC; Millar J; Woolley R; Ives N; Osman H; Moss P; Bion JF
    JAMA Intern Med; 2017 Jun; 177(6):774-783. PubMed ID: 28437539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.
    Reed DR; Petroni GR; West M; Jones C; Alfaraj A; Williams PG; DeGregory K; Grose K; Monson S; Varadarajan I; Volodin L; Donowitz GR; Kindwall-Keller TL; Ballen KK
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):61-69. PubMed ID: 36634280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
    Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
    Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy.
    Rinehart M; Hochard E; Rockey M; Abhyankar S; Ganguly S; Lin T; McGuirk J; Shune L; Singh A; Aljitawi O
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):105-11. PubMed ID: 27013276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.
    Nakagawa D; Shimomura Y; Mitsuyuki S; Kubo T; Nishikubo M; Okada N; Kamijo K; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Ishikawa T
    Int J Hematol; 2023 Sep; 118(3):347-354. PubMed ID: 37468771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytomegalovirus infection after haploidentical stem cell transplantation may reduce relapse risk in leukemia].
    Lin X; Ou Y; Long H; Huang Y; Song C; Lu Z; Guo K; Wu B; Xu J
    Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):107-10. PubMed ID: 26875578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.